IPHA Innate Pharma S.A.
$1.87▼ -1.58%
Healthcare
Other
After hours
$1.87▼ -0.53%
Sep 11, 4:10 PM ET
Volume 8.3K
Avg Volume (10D) 14.2K
Key Metrics & Fundamentals
Market Cap
$208.88M
P/E Ratio
–
Div Yield
–%
52W Range
1.17 - 2.71
% vs 50 MA
-4.69%
% vs 200 MA
6.93%
RSI-14
40.3
MACD Histogram
-0.0500
Beta (1Y vs SPY)
1.60
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
Business Wire · Sep 10, 2026 5:00 AM
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · Sep 2, 2026 5:00 AM
Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ...
GuruFocus.com · Aug 17, 2026 5:32 PM
Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative
Simply Wall St. · Aug 15, 2026 2:08 AM
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
MarketBeat · Aug 14, 2026 7:02 PM
Innate Pharma Announces Conference Call and Webcast
Business Wire · Aug 14, 2026 9:30 AM
Leerink Partners Upgrades Innate Pharma to Outperform From Market Perform, Adjusts PT to $4 From $3
MT Newswires · Aug 11, 2026 11:50 AM
Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
Pharmaceutical Technology · Aug 10, 2026 12:14 PM
Innate Pharma, Sobi Partner on Late-Stage Study for Lacutamab
MT Newswires · Aug 10, 2026 8:09 AM
Innate Pharma, Swedish Orphan Biovitrum Partner to Advance Phase 3 Lymphoma Drug; Shares Surge Pre-Bell
MT Newswires · Aug 10, 2026 7:36 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
No Reddit posts found for IPHA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.